Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15–18, Apple Safari 7, SeaMonkey 2.15-2.23

Become a member
  1. OncologyPRO
  2. Meeting Resources
  3. European Lung Cancer Congress 2022

Oncogene addicted tumours, KRAS, RET, HER2, BRAF

New drugs targeting HER2

Date

01 Apr 2022

Session

Oncogene addicted tumours, KRAS, RET, HER2, BRAF

Topics

Cytotoxic Therapy;  Targeted Therapy

Tumour Site

Presenters

Julien Mazieres

Authors

J. Mazieres

Author affiliations

  • Centre Hospitalier Universitaire de Toulouse - Hopital Larrey, Toulouse/FR

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Login

Resources from the same session

METex14

Presenter: Laura Mezquita

Session: Oncogene addicted tumours, KRAS, RET, HER2, BRAF

Resources:

Slides

Webcast

New drugs targeting RET

Presenter: Alexander Drilon

Session: Oncogene addicted tumours, KRAS, RET, HER2, BRAF

Resources:

Slides

Webcast

New drugs targeting BRAF

Presenter: David Planchard

Session: Oncogene addicted tumours, KRAS, RET, HER2, BRAF

Resources:

Slides

Webcast

Q&A

Session: Oncogene addicted tumours, KRAS, RET, HER2, BRAF

Resources:

Webcast

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings

  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.